checkAd

     121  0 Kommentare Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

    BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, will be organizing the HALLO DOC! event, informing about colorectal cancer, cutting-edge research, new treatment modalities, and holistic therapeutic approaches. This event will take place on March 20, 2024, in Berlin, Germany, aligning with the Colorectal Cancer Awareness Month.

    HALLO DOC! comes at a critical time as the incidence of colorectal cancer increases alarmingly, particularly among the youth, emphasizing the necessity for effective prevention, early detection, and the avoidance of recurrence. Mainz Biomed has organized this event to shed light on new diagnostic methods, the importance of a comprehensive treatment approach, and the latest advancements in colorectal cancer research.

    Event Highlights:

    • Expert Insights: Keynote presentations by renowned experts, including Prof. Dr. Guido Schumacher, Priv. Doz. Dr. med Annika Kurreck, Prof. Dr. Ingo Froböse, and Priv. Doz. Dr. Severin Daum, offering invaluable insights into modern colorectal cancer treatment methods, the critical role of early detection, and personalized medicine.
    • Patient Perspective: A moving account by Jule Blöhmer, a young colorectal cancer survivor, aiming to inspire and inform others about the journey through diagnosis, treatment, and recovery.
    • Interactive Sessions: Engaging Q&A sessions with the audience, both on-site and streaming online, facilitating a deeper understanding and discussion about colorectal cancer.
    • Innovative Research: Presentation of groundbreaking studies on the role of the microbiome and molecular markers in colorectal cancer prevention and treatment, highlighting Mainz Biomed's contributions to the field.
    • Networking Opportunity: A "Get Together" session to conclude the event, allowing for personal interactions among attendees, speakers, and professionals.

    Attendance:

    Mainz Biomed is at the forefront of developing market-ready, molecular-genetic diagnostic solutions for life-threatening conditions. Its flagship product, ColoAlert, offers an accurate, non-invasive, and easy-to-use at-home screening test for colorectal cancer, marking a significant advancement in early detection and prevention strategies.

    Seite 1 von 4


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, will be organizing the HALLO …

    Schreibe Deinen Kommentar

    Disclaimer